Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03119454
Other study ID # RU-FANO-10-16
Secondary ID
Status Completed
Phase N/A
First received December 9, 2016
Last updated April 13, 2017
Start date October 2016
Est. completion date December 2016

Study information

Verified date December 2016
Source Federal State Budgetary Scientific Institution, Scientific Research Institute of Rheumatology
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Evaluation of pharmacokinetic parameters of diprospan in long term when administered systemically in patients in routine medical practice.

Applied research project.

Design: open-comparative prospective cohort study.

Two groups of subjects:

- patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first,

- control group of subjects for the study of pharmacokinetic parameters diprospan and its metabolites.

Objectives of the study: to evaluate the pharmacokinetic parameters of Diprospan in the long term when administered systemically in patients in routine practice.


Description:

Design: Open-comparative prospective cohort study.

The study population: two groups of subjects

- first group: patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first administration.

- second group: the control group of subjects for the study of pharmacokinetic parameters diprospan and its metabolites.

Intramuscular injection diprospan (suspension for injection) at a dose of 1 ml (7 mg) once.

Main objective of the study: to evaluate pharmacokinetic parameters of Diprospan in the long term when administered systemically in patients in routine practice.

Objectives of the study:

- to develop laboratory analytical method of quantifying the investigated substance (betamethasone) in human urine sensitive, selective and precise method using high performance liquid chromatography with tandem mass selective detection,

- analysis of quantitative content, evaluation of pharmacokinetic parameters of diprospan in the bioassay in patients with systemic intramuscular application in routine clinical practice in the Russian Federation,

- analysis of clinical patient data and pharmacokinetic parameters of study drug in the urine of patients,

- determination of minimum number of arbitration bioassay to store,

- preparation of recommendations for systemic use of glucocorticoids in athletes, in accordance with the requirements of the all-Russian anti-doping rules and the requirements of the anti-doping rules, approved by the international anti-doping authorities.

First group (patients receiving diprospan).

Stage 1: selection of study participants from a number of patients who are administered with Diprospan" at a dose of 1 ml (7 mg) intramuscularly as standard therapy of existing disease, or multiple times, but following introduction of "Diprospan" drug is planned no earlier than 28 days after the first.

Step 2: draw the original samples for pharmacokinetic studies, a single injection of the study medication as part of routine care.

Stage 3: Sampling in dynamics for pharmacokinetic studies; assessment of clinical and laboratory parameters after a single administration of the study drug.

Stage 4: evaluation of clinical examination data and pharmacokinetic study.

Second group (control).

Stage 1: selection of study participants from a number of patients or healthy volunteers who had not received systemic or local corticosteroids in the last 12 weeks before the screening visit.

Stage 2: drawing of samples for pharmacokinetic studies.

Primary endpoints:

• betamethasone concentration in urine.

Secondary endpoints:

- evaluation of articular status,

- overall assessment of the health status of the patient,

- overall assessment of disease activity, physician assessment of disease activity criteria for SDAI, CDAI, DAS-28.

Number of patients.

First group (the study of the pharmacokinetics of the drug "Diprrospan"): at least 20 patients (10 men and 10 women).

The second group (control): at least 20 patients (10 men and 10 women).

Safety monitoring In accordance with the order of the Health Ministry of Russia №757n "Approval of the Procedure for monitoring the safety of medicinal products for medical use, registration of adverse events, serious adverse reactions, unexpected adverse reactions in the use of drugs for medical use."


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 2016
Est. primary completion date November 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Signed a voluntary informed consent form,

- Patients of both sexes aged 18 to 35 years old Caucasian,

- Verified diagnosis of rheumatoid arthritis according to criteria ACR \ EULAR 2010 or ankylosing spondylitis (axial spondyloarthritis) ASAS criteria for 2009 based on the data a detailed medical history, a standard clinical, laboratory and instrumental methods of examination,

- The presence of signs of active inflammation according to standard valuation techniques (for rheumatoid arthritis or DAS28 =3.2 CDAI=10; for ankylosing spondylitis or BASDAI=2.0 ASDAS=1.3),

- If the patient gets authorized for use in the study antirheumatic drugs (except glucocorticoids other) for treatment of the underlying disease, they should be applied in stable doses for at least six weeks before the screening visit.

- BMI should be in the range of 18.0 to 30.0 kg / m 2 ,

- Consent to use adequate methods of contraception to patients during the study period.

Exclusion Criteria:

- Allergic history,

- Drug intolerance, hypersensitivity to any of the components "Diprospan" drug,

- Severe chronic cardiovascular, bronchopulmonary, endocrine and nervous systems (including mental) and diseases of the gastrointestinal tract (GIT), liver, kidney, blood, surgical procedures on the gastrointestinal tract (except appendectomy)

- Acute infectious, non-infectious and allergic diseases in less than 4 weeks prior to visit 1,

- A positive blood test for HIV, syphilis, hepatitis B and C,

- Systolic blood pressure measured at rest after 5 minutes of exposure in the "sitting" position, below 100 mm Hg. or above 140 mm Hg and / or diastolic blood pressure below 60 mm Hg or above 90 mm Hg,

- Heart rate below 40 beats / min,

- Hemoglobin <90 g / l (9 g / dl), or hematocrit less than 30%,

- White blood cells <3.0 x 10 9 / L,

- Absolute neutrophil count (ANC) <1.0 x 10 / L,

- Serum creatinine more than 0.132 mmol / L,

- Increased ALT and / or AST 1.5 upper limit of normal,

- Clinically significant (in the opinion of the investigator) ECG changes,

- The use of systemic or local corticosteroids for the treatment of the underlying disease for the last 12 weeks before the screening visit,

- Taking any medications, in addition to permissible under study

- Plasmapheresis in less than 14 days prior to study entry,

- Participation in a clinical trial of an unregistered in the Russian Federation of a drug or device for less than 3 months prior to the study,

- The inability or unwillingness of the patient to comply with the conditions of the study program,

- Any reason for that, according to the researcher, will prevent the participation of the patient in the study,

- Pregnant or lactating women (all women should have a negative pregnancy test on the day of screening).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Diprospan
Intramuscular

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Federal State Budgetary Scientific Institution, Scientific Research Institute of Rheumatology Institute of Biomedical Chemistry, Russia, The League of Clinical Research, Russia

Outcome

Type Measure Description Time frame Safety issue
Other Overall assessment of the health status of the patient by physician Vital signs, physical examination, new diagnoses Day 28
Other Overall assessment of the health status of the patient by patient Visual analogue scale, mm Day 28
Primary Betamethasone concentration in urine Quantitative determination of study drug (betamethasone) in human urine should be conducted sensitive, selective and precise method using high performance liquid chromatography with tandem mass selective detection (HPLC-MS / MS) with a detection mode permits fragment ions not more R <70K. laboratory analytical method should be developed for the measurement of betamethasone with the definition of the limit of not less than 7.5 ng / mL. Day 28
Secondary Articular status (swelling) Number of swollen joints Day 28
Secondary Articular status (pain) Number of painful joints Day 28
Secondary Physician's assessment of disease activity Visual analogue scale, mm Day 28
Secondary Simple disease activity index SDAI Scale: remission; low activity; moderate activity; high activity Day 28
Secondary Clinical disease activity index CDAI Scale: remission; low activity; moderate activity; high activity Day 28
Secondary Disease activity score DAS28 Scale: remission; low activity; moderate activity; high activity Day 28
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06040853 - Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia? Phase 4
Not yet recruiting NCT05553496 - Assessment of Rituximab Therapeutic Response Versus Conventional Treatment Phase 2/Phase 3
Recruiting NCT05534802 - Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass N/A
Recruiting NCT04190537 - PARADOX - the Incidence of Paradoxical Reactions in Pediatric Patients Premedicated With Midazolam
Completed NCT03522532 - Dental Restorations Effect on Oxidative Status of the Gingival Crevicular Fluid N/A
Unknown status NCT01614353 - Medication-taking Preferences & Practices of Patients With Chronic Conditions N/A
Completed NCT03714360 - The Effect of Tranexamic Acid. A Randomised Study of Patients Undergoing Elective Lumbar Spine Surgery. Phase 4
Recruiting NCT03352622 - Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis N/A
Recruiting NCT06288841 - Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in Gynecologic Laparoscopic Patients: A Randomized, Single-blind, Active-Controlled Clinical Study N/A
Not yet recruiting NCT04320277 - Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. Phase 2/Phase 3
Completed NCT03359590 - Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients Phase 2
Completed NCT05591105 - Morphine Consumption in the Obese Patients
Not yet recruiting NCT03904303 - Test of a New Gel-based Colon Cleansing Agent Compared to Moviprep Phase 1
Not yet recruiting NCT05453045 - Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva N/A
Completed NCT05428683 - Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery N/A
Enrolling by invitation NCT02985281 - Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients Phase 2/Phase 3
Recruiting NCT06222710 - Ultrasound Guiding Pharmacopuncture Therapy for Supraspinatus Tendinopathy N/A
Not yet recruiting NCT03953287 - Pharmacokinetic Study of Paracetamol. Phase 1
Recruiting NCT03622047 - Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil N/A
Active, not recruiting NCT06324370 - Exploratory Pharmacokinetic Study of Virgin Coconut Oil (VCO) N/A